Cargando…

A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis

Cardiovascular magnetic resonance (CMR) plays an important clinical role for diagnosis and therapy monitoring of cardiac amyloidosis (CA). Previous data suggested a lower native T1 value in spite of a higher LV mass and higher extracellular volume fraction (ECV) value in wild-type transthyretin amyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamling, Bishwas, Bietenbeck, Michael, Drakos, Stefanos, Korthals, Dennis, Vehof, Volker, Stalling, Philipp, Meier, Claudia, Yilmaz, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758193/
https://www.ncbi.nlm.nih.gov/pubmed/36526658
http://dx.doi.org/10.1038/s41598-022-26216-9
_version_ 1784851990342270976
author Chamling, Bishwas
Bietenbeck, Michael
Drakos, Stefanos
Korthals, Dennis
Vehof, Volker
Stalling, Philipp
Meier, Claudia
Yilmaz, Ali
author_facet Chamling, Bishwas
Bietenbeck, Michael
Drakos, Stefanos
Korthals, Dennis
Vehof, Volker
Stalling, Philipp
Meier, Claudia
Yilmaz, Ali
author_sort Chamling, Bishwas
collection PubMed
description Cardiovascular magnetic resonance (CMR) plays an important clinical role for diagnosis and therapy monitoring of cardiac amyloidosis (CA). Previous data suggested a lower native T1 value in spite of a higher LV mass and higher extracellular volume fraction (ECV) value in wild-type transthyretin amyloidosis (ATTRwt) compared to light-chain amyloidosis (AL)—resulting in the still unsolved “native T1 vs. ECV paradox” in CA. The purpose of this study was to address this paradox. The present study comprised N = 90 patients with ATTRwt and N = 30 patients with AL who underwent multi-parametric CMR studies prior to any specific treatment. The CMR protocol comprised cine- and late-gadolinium-enhancement (LGE)-imaging as well as T2-mapping and pre-/post-contrast T1-mapping allowing to measure myocardial ECV. Left ventricular ejection fraction (LV-EF), left ventricular mass index (LVMi) and left ventricular wall thickness (LVWT) were significantly higher in ATTRwt in comparison to AL. Indexed ECV (ECVi) was also higher in ATTRwt (p = 0.041 for global and p = 0.001 for basal septal). In contrast, native T1- [1094 ms (1069–1127 ms) in ATTRwt vs. 1,122 ms (1076–1160 ms) in AL group, p = 0.040] and T2-values [57 ms (55–60 ms) vs. 60 ms (57–64 ms); p = 0.001] were higher in AL. Considering particularities in myocardial density, “total extracellular mass” (TECM) was substantially higher in ATTRwt whereas “total intracellular mass” (TICM) was rather similar between ATTRwt and AL. Consequently, the “ratio TICM/TECM” was lower in ATTRwt compared to AL (0.58 vs. 0.83; p = 0.007). Our data confirm the presence of a “native T1 vs. ECV paradox” with lower native T1 values in spite of higher myocardial mass and ECV in ATTRwt compared to AL. Importantly, this observation can be explained by particularities regarding myocardial density that result in a lower TICM/TECM “ratio” in case of ATTRwt compared to AL—since native T1 is determined by this ratio.
format Online
Article
Text
id pubmed-9758193
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-97581932022-12-18 A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis Chamling, Bishwas Bietenbeck, Michael Drakos, Stefanos Korthals, Dennis Vehof, Volker Stalling, Philipp Meier, Claudia Yilmaz, Ali Sci Rep Article Cardiovascular magnetic resonance (CMR) plays an important clinical role for diagnosis and therapy monitoring of cardiac amyloidosis (CA). Previous data suggested a lower native T1 value in spite of a higher LV mass and higher extracellular volume fraction (ECV) value in wild-type transthyretin amyloidosis (ATTRwt) compared to light-chain amyloidosis (AL)—resulting in the still unsolved “native T1 vs. ECV paradox” in CA. The purpose of this study was to address this paradox. The present study comprised N = 90 patients with ATTRwt and N = 30 patients with AL who underwent multi-parametric CMR studies prior to any specific treatment. The CMR protocol comprised cine- and late-gadolinium-enhancement (LGE)-imaging as well as T2-mapping and pre-/post-contrast T1-mapping allowing to measure myocardial ECV. Left ventricular ejection fraction (LV-EF), left ventricular mass index (LVMi) and left ventricular wall thickness (LVWT) were significantly higher in ATTRwt in comparison to AL. Indexed ECV (ECVi) was also higher in ATTRwt (p = 0.041 for global and p = 0.001 for basal septal). In contrast, native T1- [1094 ms (1069–1127 ms) in ATTRwt vs. 1,122 ms (1076–1160 ms) in AL group, p = 0.040] and T2-values [57 ms (55–60 ms) vs. 60 ms (57–64 ms); p = 0.001] were higher in AL. Considering particularities in myocardial density, “total extracellular mass” (TECM) was substantially higher in ATTRwt whereas “total intracellular mass” (TICM) was rather similar between ATTRwt and AL. Consequently, the “ratio TICM/TECM” was lower in ATTRwt compared to AL (0.58 vs. 0.83; p = 0.007). Our data confirm the presence of a “native T1 vs. ECV paradox” with lower native T1 values in spite of higher myocardial mass and ECV in ATTRwt compared to AL. Importantly, this observation can be explained by particularities regarding myocardial density that result in a lower TICM/TECM “ratio” in case of ATTRwt compared to AL—since native T1 is determined by this ratio. Nature Publishing Group UK 2022-12-16 /pmc/articles/PMC9758193/ /pubmed/36526658 http://dx.doi.org/10.1038/s41598-022-26216-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Chamling, Bishwas
Bietenbeck, Michael
Drakos, Stefanos
Korthals, Dennis
Vehof, Volker
Stalling, Philipp
Meier, Claudia
Yilmaz, Ali
A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis
title A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis
title_full A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis
title_fullStr A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis
title_full_unstemmed A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis
title_short A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis
title_sort compartment-based myocardial density approach helps to solve the native t1 vs. ecv paradox in cardiac amyloidosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758193/
https://www.ncbi.nlm.nih.gov/pubmed/36526658
http://dx.doi.org/10.1038/s41598-022-26216-9
work_keys_str_mv AT chamlingbishwas acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT bietenbeckmichael acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT drakosstefanos acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT korthalsdennis acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT vehofvolker acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT stallingphilipp acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT meierclaudia acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT yilmazali acompartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT chamlingbishwas compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT bietenbeckmichael compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT drakosstefanos compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT korthalsdennis compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT vehofvolker compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT stallingphilipp compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT meierclaudia compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis
AT yilmazali compartmentbasedmyocardialdensityapproachhelpstosolvethenativet1vsecvparadoxincardiacamyloidosis